CPC C07K 14/70596 (2013.01) [A61K 38/177 (2013.01); A61K 38/1709 (2013.01); A61K 38/208 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 1/00 (2018.01); A61P 35/00 (2018.01); A61P 37/00 (2018.01); C07K 14/5434 (2013.01); C07K 16/244 (2013.01); C07K 16/2896 (2013.01); C12N 15/1136 (2013.01); C12N 15/1138 (2013.01); A61K 2039/575 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/20 (2017.05)] | 2 Claims |
1. A method of suppressing an immune response in a subject, the method comprising administering to the subject a therapeutically effective amount of
a recombinant soluble CD5L:p40 heterodimer, wherein the subject has an autoimmune disease.
|